Investor Presentaiton

BION-206: Summary OPTIONAL A novel regulatory mechanism discovered by Biond in the CD28/B7 axis (1st in class) Lead BION-206 agent was selected and is under pre- clinical development BION-206 binds to the shedding region of CD28 and sterically hinders cleavage resulting in augment T cells activation Targets solid tumors with immune infiltration in patients with unresectable or metastatic disease, including anti-PD1 refractory patients BIOND BIOLOGICS Biond Biologics Corporate Presentation | May 2021 | Non-confidential 24 24

View entire presentation